MEDG Medgenics(Regs)

    Medgenics, Inc.
                         ("Medgenics" or the "Company")
                                        
                 Lord Steinberg Appointed Non-Executive Director
                                        
1 February 2008

Medgenics (AIM: MEDG), the US incorporated biopharmaceutical company  that  was
admitted to AIM in December 2007, is pleased to announce the appointment of Lord
Steinberg  to  the Company's Board, as a non-executive director  with  immediate
effect.

A  Life Peer and active member of the House of Lords in the United Kingdom, Lord
Steinberg is the founder, former Chairman and Life President of Genting  Stanley
plc  (formerly  Stanley Leisure plc).  Stanley Leisure plc was  acquired  for  a
consideration  of �639 million in 2006 by Genting International Investment  (UK)
Ltd, part of the Malaysian group Genting Berhad which is listed on the Singapore
Exchange.   At the time of the acquisition Stanley Leisure plc was  the  largest
casino operator in the UK, owning 45 casinos, 4 in London and 41 throughout  the
rest of the UK.

In  1997 and 1998 Lord Steinberg received awards for North West Business  Person
of  the  Year.   In  July  1999  he was awarded an  Honorary  Doctorate  by  the
University  of  Salford.  He also sits on many charitable  committees  including
Crimestoppers Trust.

Commenting on the appointment, Medgenics' CEO, Dr. Andrew Pearlman said:

"Following Medgenics' successful admission to AIM last month, I am delighted  to
be  able  to  welcome Lord Steinberg to the Board.  He is one of the  UK's  most
successful  and  respected businessmen, with substantial experience  of  the  UK
stock market.  The fact that he has chosen to join the Board of directors of the
Company  offers  great  support to Medgenics' technology, business  and  overall
market  opportunity.  I and the rest of the Board look forward to  the  valuable
contribution he will make to the Company."

FORMAL DISCLOSURE

The  Company  makes  the  following formal disclosure  in  connection  with  the
above-mentioned appointment:

Full name: Lord Leonard Steinberg
Age: 71

Directorships or partnerships current or held in the previous 5 years:

Current Directorships                           Appointed
                                                            
Wilbraham Road (Manchester)Trust Limited        23 September 2002
Crimestoppers Trust                             18 May 2005
L Sports Investments Limited                    23 May 2007
StanleyBet Holdings Limited                     30 July 2007
StanleyBet Overseas Investments Limited         30 August 2007

Past Directorships                              Resigned
                                                            
British Casino Association Limited              17 September 2006
Genting Stanley Plc                             31 December 2006
Stanley Casinos Limited                         10 September 2003
Wilstan Racing Limited                          10 September 2003
Star TYP Investments Limited                    13 November 2007 *
Livermore Investments Group Limited **          31 October 2006

*   date of dissolution of the company - Star TYP Investments Limited did not
    trade and was struck off pursuant to an application from the company and
    dissolved on 13 November 2007
**  a British Virgin Islands company traded on AIM, formerly Empire Online Limited

Save as disclosed above, there is no other information required to be disclosed
under Schedule 2, paragraph (g) of the AIM Rules for Companies.

For further information, contact:

Medgenics, Inc.                                +972 4 958 8555
Dr. Andrew L. Pearlman

Citigate Dewe Rogerson                         +44 (0)207 638 9571
Mark Swallow
Jonathan Shillington (Global Consulting Group) +44 (0)7900 053 536

Blomfield Corporate Finance Limited            +44 (0)207 512 0191
James Pinner
Alan MacKenzie

SVS Securities plc                             +44 (0)207 638 5600
Peter Manfield
Ian Callaway

Notes to Editors:

Medgenics was admitted to AIM on 4 December 2007.  The Admission to AIM followed
the  Company's successful fund raising with investors, which raised a  total  of
�3.28 million.

The  group's research & development and administrative operations are  conducted
by  Medgenics  Medical (Israel) Limited, the Company's wholly owned  subsidiary,
from premises in Karmiel, Israel (together the "Group").

*    The Group is at the clinical trial stage of testing the safety and efficacy
     of its proprietary 'biological pump', the "Biopump" and associated technologies
     (together the "Biopump Platform Technology").
     
*    The Biopump is made from a toothpick-sized sample of the patients' own skin
     dermal  tissue,  which  is  processed  outside  the  body  and  reimplanted
     subcutaneously 1-2 weeks later.
     
*    The Biopump enables patients to produce, on a long-term basis, their own
     natural human protein therapy.  The Biopump is targeted at a range of chronic
     diseases, including anaemia and hepatitis C.
     
*    Biopumps are designed to replace costly factory-produced proteins delivered
     via frequent and painful injections.  These injected protein therapies can have
     associated adverse side effects.
     
*    The worldwide market for protein therapy was valued at over US $51 billion
     in 2005 and is forecast to reach US $87 billion by 2010.  The Directors estimate
     that  the  Biopump Platform Technology could potentially be  applied  to  a
     substantial part of this market.
     
*    The Directors believe that the Biopump Platform Technology provides a wide
     range of advantages over existing therapies.  These advantages should appeal to,
     and offer benefits to, doctors, patients and third-party payers (e.g. medical
     insurers).
     
*     The  Group  plans to commence a Phase I/II Clinical Trial aimed  at  the
     treatment of anaemia during the second quarter of 2008.  In 2006, Erythropoietin
     ("EPO") injections for the treatment of anaemia generated revenues of US $11.9
     billion.
     
*    The Company expects to obtain key initial safety and proof of efficacy data
     three-to-five months after the above trial commences.

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024